The stock of Chemours Co (NYSE:CC) hit a new 52-week high and has $24.90 target or 31.00% above today’s $19.01 share price. The 6 months bullish chart indicates low risk for the $3.41 billion company. The 1-year high was reported on Nov, 7 by Barchart.com. If the $24.90 price target is reached, the company will be worth $1.06B more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. About 1.14 million shares traded hands. Chemours Co (NYSE:CC) has risen 139.83% since April 5, 2016 and is uptrending. It has outperformed by 137.88% the S&P500.
Chemours Co (NYSE:CC) Ratings Coverage
Out of 8 analysts covering Chemours (NYSE:CC), 3 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 38% are positive. $19 is the highest target while $5.25 is the lowest. The $11.38 average target is -40.14% below today’s ($19.01) stock price. Chemours has been the topic of 16 analyst reports since July 27, 2015 according to StockzIntelligence Inc. JP Morgan upgraded the stock to “Neutral” rating in Friday, August 7 report. Citigroup maintained Chemours Co (NYSE:CC) on Monday, April 18 with “Neutral” rating. The stock has “Underweight” rating given by JP Morgan on Friday, August 7. The rating was initiated by Argus Research on Friday, September 18 with “Hold”. Goldman Sachs upgraded the shares of CC in a report on Monday, March 14 to “Buy” rating. The company was maintained on Thursday, August 11 by Citigroup. The stock of Chemours Co (NYSE:CC) earned “Sell” rating by UBS on Tuesday, August 18. As per Wednesday, August 10, the company rating was upgraded by Argus Research. The stock of Chemours Co (NYSE:CC) earned “Neutral” rating by Citigroup on Friday, August 14. The stock of Chemours Co (NYSE:CC) earned “Hold” rating by Jefferies on Tuesday, February 16.
According to Zacks Investment Research, “Chemours Company is involved in chemical business. It operating segment consists of Titanium Technologies, Fluoroproducts and Chemical Solutions. Titanium Technologies segment produces titanium dioxide and premium white pigment. Fluoroproducts segment provides fluoroproducts, refrigerants and industrial fluoropolymer resins. Chemical Solutions segment provides industrial and specialty chemicals. The company’s brand consists of Teflon(R), Ti-Pure(R), Krytox(R) Viton(R), Opteon(R) and Nafion(R). Chemours Company is headquartered in Wilmington.”
More notable recent Chemours Co (NYSE:CC) news were published by: Investorplace.com which released: “Trade of the Day: Chemours Co (NYSE:CC)” on October 26, 2016, also Fool.com with their article: “Chemours Co Surges After New Jury Verdict” published on July 08, 2016, Valuewalk.com published: “Chemours Co (CC) â€œMost Morally And Financially Bankrupt Companyâ€ Ever: Citron …” on June 02, 2016. More interesting news about Chemours Co (NYSE:CC) were released by: Valuewalk.com and their article: “Chemours Co (CC) Starts To Rally After Tanking On Wednesday” published on July 07, 2016 as well as Fool.com‘s news article titled: “Here’s Why Chemours Co Stock Popped Today” with publication date: February 24, 2016.
CC Company Profile
The Chemours Company, incorporated on February 18, 2014, is a well-known provider of performance chemicals. The Firm operates through three divisions: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Company’s Titanium Technologies segment produces titanium dioxide (TiO2). The Company’s Fluoroproducts segment provides fluoroproducts, such as refrigerants and industrial fluoropolymer resins. The Company’s Chemical Solutions segment provides industrial and specialty chemicals used in gold production, oil refining, agriculture, industrial polymers and other industries. The Firm operates approximately 30 production facilities located in over 10 countries and serves a range of end markets in over 130 countries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.